 |
| Anno I | Numero 5 | Settembre 2016 |
| Comitato scientifico editoriale: Sergio Bracarda, Giacomo Cartenì, Giuseppe Procopio Editore: Intermedia – Direttore Responsabile: Mauro Boldrini |
| Notizie dalla ricerca |
Tumor mutational load and immune parameters across metastatic Renal Cell Carcinoma (mRCC) risk groups |
| Patients with metastatic renal cell carcinoma (mRCC) have better overall survival when treated with nivolumab, a cancer immunotherapy that targets the immune checkpoint inhibitor programmed cell death 1 (PD-1), rather than everolimus (a chemical inhibitor of mTOR and immunosuppressant). Poor-risk mRCC patients treated with nivolumab seemed to experience the greatest overall survival benefit, compared to patients with favorable or intermediate-risk, in an analysis of the CheckMate-025 … |
| Continua a leggere |
| Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms |
| Second-line systemic treatment options for metastatic clear cell renal cell cancer (mccRCC) are diverse and treatment strategies are variable among experts. Our aim was to investigate the approach for the second-line treatment after first-line therapy with a tyrosine kinase inhibitor (TKI). Recently two phase III trials have demonstrated a potential role for nivolumab (NIV) and cabozantinib (CAB) in this setting. We aimed to estimate the impact of these trials on clinical decision making. Eleven international experts … |
| Continua a leggere |
| Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma |
| The management of advanced renal cell carcinoma (RCC) has dramatically changed over the past decade. Therapies that target the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways have considerably expanded treatment options; however, most patients with advanced RCC still have limited overall survival. Increased understanding of the mechanisms of T cell-antigen recognition and function has led to the development of novel immunotherapies to … |
| Continua a leggere |
| Checkpoint Blockade – a New Treatment Paradigm in Renal Cell Carcinoma |
| Nivolumab is the first checkpoint inhibitor for the treatment of renal cell carcinoma (RCC), which is in line for approval in Europe. Despite its novelty in the treatment algorithm of RCC, it offers a whole new strategy of therapy management with safe applicability. The aim of this work was to review current data on checkpoint inhibitors in RCC and discuss future perspectives for this novel approach in RCC. A selective literature search was performed in the Pubmed database: Nivolumab is a first-in-class agent for … |
| Continua a leggere |
| Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions |
| Immunotherapy with checkpoint inhibitors has arrived and begun to change the landscape of clinical oncology, including for patients with renal cell carcinoma. Specifically, drugs targeting the programmed death 1 and cytotoxic T-lymphocyte associated antigen pathways have demonstrated remarkable responses for patients in clinical trials. In this article, we review the most recent available data for immune checkpoint inhibitors for patients with renal cell carcinoma. We discuss potential strategies for … |
| Continua a leggere |
| Appuntamenti AIOM |
| XVIII Congresso Nazionale AIOM |
| Roma, 28 – 30 ottobre 2016 |
| Link all'evento |
| Immunotherapy: Past, present and Future |
| Napoli, 26 settembre 2016 |
| AIOM-AIRTUM: Presentazione Volume "I Numeri del Cancro in Italia 2016" |
| Roma, 27 settembre 2016 |
| Immuno-Oncologia: Stato dell'arte e update |
| Bari, 29 settembre 2016 Evento riservato ai Soci della Puglia |
| Combinazioni e sequenze in terapia: Aspetti clinico-metodologici e farmacoeconomici |
| Roma, 29 – 30 settembre 2016 |
| XII Congresso Regionale AIOM Sardegna |
| Oliena (NU), 30 settembre – 1 ottobre 2016 |
| Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà |
| Milano, 11 ottobre 2016 |
| Dialoghi sull'immunoterapia dei tumori dell'AIOM Campania |
| Benevento, 18 ottobre 2016 |
| Dialoghi sull'immunoterapia dei tumori dell'AIOM Campania |
| Napoli, 20 ottobre 2016 |
| Hot Topics in Oncologia 2016 |
| Fiuggi (FR), 22 ottobre 2016 |
| NeVento-01 – 1° Meeting Annuale sulle Neoplasie Vescicali Gruppo NeVe |
| Milano, 3 novembre 2016 |
| 4th International Conference 'Translational Research in Oncology' |
| Meldola (FC), 8 novembre 2016 Forlì, 9 – 11 novembre 2016 |
| IV Meeting Uro-Oncologico: Update 2016 sui tumori urologici |
| Fano (PU), 11 – 12 novembre 2016 |
| Nuove Frontiere Diagnostico-Terapeutiche nelle Neoplasie Polmonari, Renali e nel Melanoma |
| Varese, 12 novembre 2016 |
| 5th World Top Communications of the Year in Genito-Urinary Oncology |
| Arezzo, 17 – 18 novembre 2016 |
| Questi e altri appuntamenti si possono consultare sul sito AIOM www.aiom.it |
| Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001 Per contattare la redazione e commentare le notizie clicca qui: redazione Per consultare i numeri arretrati della newsletter clicca qui: archivio Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI |
Questo progetto è stato realizzato con il contributo di  |